Diligence memo · auto-generated · as of July 2, 2026

Realm Therapeutics plc

Realm Therapeutics plc looks fair against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Realm Therapeutics plc operates in Pharmaceuticals, based in LONDON.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Realm Therapeutics plc has raised $21M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $21M on 2017-10-10.

Most recent recorded round closed around 2017-10-10.

Valuation (modeled)modeled

Provath models Realm Therapeutics plc at approximately $697M (range $43M–$2.7B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.03× the median modeled value of Series B Pharmaceuticals companies in 2016–2018 (40 peers) — value vs value, same stage and era. Within the normal band (103% of peer median) for its niche.

Financing rhythm & timingmixed

Last raise 8.7 yr ago; this sector typically re-raises about every 13 months.

Only one round on record and long silent — often defunct, acquired, or gone quiet.

Comparablesmixed

Capital scale ranks ahead of 67% of Pharmaceuticals peers (1613 compared).

Modeled value ranks above 85% of those peers.

Closest niche peers: LP Investors, LLC, GigaGen, Inc., Vitality Biopharma, Inc., Madrigal Pharmaceuticals, Inc., Slayback Pharma Ltd Liability Co.

Peoplefiled

8 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.